BackSAB Biotherapeutics Overview

SAB Biotherapeutics Receivables

SAB Biotherapeutics's receivables is $1.6M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.56M
↑ 7171.40% YoYΔ $1.53M vs prior year quarter

Peer average

Loading

SAB Biotherapeutics Receivables History

Loading

SAB Biotherapeutics vs. peers: Receivables Comparison

Loading

SAB Biotherapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

SAB Biotherapeutics (SABS) FAQ

SAB Biotherapeutics (SABS) currently reports a receivables of $1.6M as of March 2026. That compares with $21K in the prior-year period — up 7171.4% year over year. Use the charts on this page to explore SAB Biotherapeutics's receivables history and peer comparisons.

SAB Biotherapeutics's receivables increased from $21K to $1.6M — a 7171.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SAB Biotherapeutics reported $1.6M in receivables as of March 2026. That compares with $21K in the prior-year period — up 7171.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for SAB Biotherapeutics, and consider following SABS for alerts when major investors trade the stock.